BackgroundThis pilot study investigated changes in remyelinating and demyelinating activity in normal appearing brain tissue (NABT) and lesions, by using voxel-wise magnetization transfer ratio (VW-MTR), in patients with relapsing–remitting multiple sclerosis (RRMS) receiving interferon beta-1a 44 mcg subcutaneously (IFN β-1a SC) three times weekly versus healthy controls (HCs) (NCT01085318).MethodsIncreasing (suggestive of remyelination) and decreasing (suggestive of demyelination) VW-MTR changes in NABT and in T2, T1 and gadolinium (Gd)-enhancing lesion volume were measured over 24 weeks in 23 patients treated with IFN β-1a SC and in 15 HCs (where applicable). VW-MTR changes were tested using the Wilcoxon signed–rank or Wilcoxon rank–sum ...
BACKGROUND: Interferon beta reduces activity in multiple sclerosis as measured clinically and by mag...
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and by magn...
Background: The EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative ...
BackgroundThis pilot study investigated changes in remyelinating and demyelinating activity in norma...
This pilot study investigated changes in remyelinating and demyelinating activity in normal appearin...
BACKGROUND AND PURPOSE: To determine whether occult disease fluctuates with macroscopic lesions duri...
Background and purpose: In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients w...
Background: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring ...
The ability of recombinant human interferon beta-1a (rh-IFN beta-1a) to suppress multiple sclerosis ...
Abstract Background Brain volume atrophy is observed in relapsing–remitting multiple sclerosis (RRMS...
Studies have shown a relationship between increased iron content and clinical progression, cognitive...
We investigated whether interferon-beta1a modifies the course of new enhancing lesions in relapsing-...
To evaluate whether recombinant human interferon-beta-1a significantly affects disease activity as m...
OBJECTIVE: In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimatel...
BACKGROUND AND PURPOSE: To define the predictive value of clinical and magnetic resonance imaging (M...
BACKGROUND: Interferon beta reduces activity in multiple sclerosis as measured clinically and by mag...
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and by magn...
Background: The EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative ...
BackgroundThis pilot study investigated changes in remyelinating and demyelinating activity in norma...
This pilot study investigated changes in remyelinating and demyelinating activity in normal appearin...
BACKGROUND AND PURPOSE: To determine whether occult disease fluctuates with macroscopic lesions duri...
Background and purpose: In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients w...
Background: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring ...
The ability of recombinant human interferon beta-1a (rh-IFN beta-1a) to suppress multiple sclerosis ...
Abstract Background Brain volume atrophy is observed in relapsing–remitting multiple sclerosis (RRMS...
Studies have shown a relationship between increased iron content and clinical progression, cognitive...
We investigated whether interferon-beta1a modifies the course of new enhancing lesions in relapsing-...
To evaluate whether recombinant human interferon-beta-1a significantly affects disease activity as m...
OBJECTIVE: In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimatel...
BACKGROUND AND PURPOSE: To define the predictive value of clinical and magnetic resonance imaging (M...
BACKGROUND: Interferon beta reduces activity in multiple sclerosis as measured clinically and by mag...
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and by magn...
Background: The EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative ...